Kazazian Asset Management’s Puma Biotechnology PBYI Stock Holding History

Kazazian Asset Management’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-6,962	Closed	-$270K	–	68
2019 Q1	$270K	Buy	+6,962	New	+$213K	0.38%	45
2018 Q4	–	Sell	-15,035	Closed	-$689K	–	78
2018 Q3	$689K	Buy	15,035 +6,264	+71%	+$302K	0.65%	38
2018 Q2	$519K	Buy	8,771 +1,614	+23%	+$93.5K	0.48%	42
2018 Q1	$487K	Buy	7,157 +2,602	+57%	+$195K	0.51%	46
2017 Q4	$450K	Buy	4,555 +472	+12%	+$52.8K	0.46%	51
2017 Q3	$489K	Buy	4,083 +1,690	+71%	+$157K	0.6%	37
2017 Q2	$209K	Buy	+2,393	New	+$134K	0.32%	46

Other funds holding PBYI

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Kazazian Asset Management's PBYI Position: Q2 2019 in Review

Kazazian Asset Management sold out of Puma Biotechnology (PBYI) in Q2 2019, closing a stake of 6,962 shares — an estimated $270K sold.

Kazazian Asset Management first reported a position in PBYI in Q2 2017 and held it in 7 quarters. The position peaked at $689K in Q3 2018. 139 funds tracked by Wall St. Rank hold PBYI as of Q2 2019.

Kazazian Asset Management reported no remaining Puma Biotechnology position as of Q2 2019 after selling out during the quarter.
Kazazian Asset Management sold 6,962 Puma Biotechnology shares in Q2 2019, an estimated $270K.
Kazazian Asset Management first reported a position in Puma Biotechnology in Q2 2017 and held it in 7 quarters.
Kazazian Asset Management's Puma Biotechnology position peaked at $689K in Q3 2018.
139 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2019.

Based on Kazazian Asset Management's 13F filing for Q2 2019, filed 14 Aug 2019.